Researchers around the world working on a cure for cancer metastasis and a medicine to better manage HIV infection
Medical researchers around the world are making progress in their attempt to find a cure for cancer. In India, researchers from the Bose Institute managed to develop a medicine that can block the spread of cancer cells or cancer metastasis. Also, a hospital in Paris is confirming that a drug usually used to treat patients with lung, skin, and kidney cancer can be applied in minimizing HIV cells.
The findings of the researchers from Bose Institute indicate that the anti-metastasis medicine attacks the spread of cancer cells in a patient. The researchers are still in the middle of confirming the volume of the medicine and its ability to attack the pathway of cancer cells.
During an interview with the Times of India, Chief Researcher Subhranshu Chatterjee said, "due to that RNA (Ribonucleic acid), cancer cells spread in the body. Our target was to confirm that and after 6 years of research, we have succeeded." The medicine will soon be tested on 40 patients to evaluate its effectivity before going into the clinic.
Meanwhile, a 51-year-old man was given the drug Nivolumab at the Pitie-Salpetriere Hospital in Paris. Nivolumab is commonly used for patients with lung cancer. After taking the medicine, medical practitioners in the hospital were able to monitor a sudden decrease of reservoirs of cells in the old man. The reservoirs cells were then revealed to be the common hideout of HIV cells. The hospital stated that the medicine and its effect to HIV patients are not yet confirmed. However, professionals from the hospital are looking forward to further results in order to determine if Nivolumab is legit for the sake of HIV/AIDS patients.
In other news, the Windsor Cancer Research Group in Canada has recently reported that information about the effectiveness of dandelion roots to cure cancer is not valid. This is to answer several articles about dandelion roots being able to kill 98 percent of cancer cells in only 48 hours.
WCRG Clinical director of the research group Dr. Caroline Hamm stated that the articles are exaggerated.
